Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 6/20 | 0.48 |
| ▸ | PIK3C3 | Q8NEB9 | 12/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15051361 | 0.80 | NR3C2 (0.42) | NR3C2PIK3C3MAPK8MAPK9MAPK10 | |
| SCHEMBL15051550 | 0.79 | MAPK10 (0.43) | NR3C2PIK3C3MAPK8MAPK9MAPK10 | |
| SCHEMBL15051461 | 0.77 | GSK3B (0.45) | NR3C2PIK3C3MAPK8MAPK9MAPK10 | |
| SCHEMBL15051271 | 0.74 | MAPK14 (0.48) | NR3C2PIK3C3MAPK10GSK3B | |
| SCHEMBL15051020 | 0.73 | PIK3C3 (0.47) | NR3C2PIK3C3GSK3B | |
| SCHEMBL25594662 | 0.72 | RAF1 (0.45) | NR3C2PIK3C3 | |
| SCHEMBL25700262 | 0.68 | PIK3C3 (0.41) | NR3C2PIK3C3MAPK10 | |
| SCHEMBL15051156 | 0.67 | PIK3C3 (0.42) | PIK3C3MAPK8MAPK9MAPK10GSK3B | |
| SCHEMBL19706556 | 0.66 | PIK3C3 (0.53) | PIK3C3GSK3B | |
| SCHEMBL15051225 | 0.66 | NR3C2 (0.47) | NR3C2PIK3C3GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165483-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | claimed |
| WO-2013096637-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| US-20130165483-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165483-A1 | HETEROARYLS AND USES THEREOF | PIK3R5, PIK3R4, PIK3C2B | NR3C2 3161/4885PIK3C3 143/4885MAPK8 543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.